| Identification | Back Directory | [Name]
AM-1638 | [CAS]
1142214-62-7 | [Synonyms]
AM-1638
AM 1638,AM1638
Benzenepropanoic acid, β-cyclopropyl-3-[[2-(5,5-dimethyl-1-cyclopenten-1-yl)-2'-fluoro-5'-methoxy[1,1'-biphenyl]-4-yl]methoxy]-, (βS)- | [Molecular Formula]
C33H35FO4 | [MDL Number]
MFCD25976578 | [MOL File]
1142214-62-7.mol | [Molecular Weight]
514.64 |
| Chemical Properties | Back Directory | [Boiling point ]
657.4±55.0 °C(Predicted) | [density ]
1.193±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (485.79 mM) | [form ]
Solid | [pka]
4.61±0.10(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC50 of 0.16 μM. | [in vivo]
AM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its antidiabetic properties in mouse, rat, and cynomologus monkey. Moreover, oral administration of full agonist AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%). AM-1638
exhibits antidiabetic activity in BDF/DIO mice[1]. | [References]
[1] Brown SP, et al. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. ACS Med Chem Lett. 2012 Aug 15;3(9):726-30. DOI:10.1021/ml300133f |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
www.weikeqi-biotech.com/ |
|